1
|
Chao MN, Chezal JM, Debiton E, Canitrot D, Witkowski T, Levesque S, Degoul F, Tarrit S, Wenzel B, Miot-Noirault E, Serre A, Maisonial-Besset A. A Convenient Route to New (Radio)Fluorinated and (Radio)Iodinated Cyclic Tyrosine Analogs. Pharmaceuticals (Basel) 2022; 15:ph15020162. [PMID: 35215275 PMCID: PMC8877694 DOI: 10.3390/ph15020162] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2021] [Revised: 01/24/2022] [Accepted: 01/25/2022] [Indexed: 02/04/2023] Open
Abstract
The use of radiolabeled non-natural amino acids can provide high contrast SPECT/PET metabolic imaging of solid tumors. Among them, radiohalogenated tyrosine analogs (i.e., [123I]IMT, [18F]FET, [18F]FDOPA, [123I]8-iodo-L-TIC(OH), etc.) are of particular interest. While radioiodinated derivatives, such as [123I]IMT, are easily available via electrophilic aromatic substitutions, the production of radiofluorinated aryl tyrosine analogs was a long-standing challenge for radiochemists before the development of innovative radiofluorination processes using arylboronate, arylstannane or iodoniums salts as precursors. Surprisingly, despite these methodological advances, no radiofluorinated analogs have been reported for [123I]8-iodo-L-TIC(OH), a very promising radiotracer for SPECT imaging of prostatic tumors. This work describes a convenient synthetic pathway to obtain new radioiodinated and radiofluorinated derivatives of TIC(OH), as well as their non-radiolabeled counterparts. Using organotin compounds as key intermediates, [125I]5-iodo-L-TIC(OH), [125I]6-iodo-L-TIC(OH) and [125I]8-iodo-L-TIC(OH) were efficiently prepared with good radiochemical yield (RCY, 51–78%), high radiochemical purity (RCP, >98%), molar activity (Am, >1.5–2.9 GBq/µmol) and enantiomeric excess (e.e. >99%). The corresponding [18F]fluoro-L-TIC(OH) derivatives were also successfully obtained by radiofluorination of the organotin precursors in the presence of tetrakis(pyridine)copper(II) triflate and nucleophilic [18F]F− with 19–28% RCY d.c., high RCP (>98.9%), Am (20–107 GBq/µmol) and e.e. (>99%).
Collapse
Affiliation(s)
- Maria Noelia Chao
- Inserm, Imagerie Moléculaire et Stratégies Théranostiques, UMR 1240, Université Clermont Auvergne, F-63000 Clermont-Ferrand, France; (M.N.C.); (J.-M.C.); (E.D.); (D.C.); (T.W.); (S.L.); (F.D.); (S.T.); (E.M.-N.); (A.S.)
| | - Jean-Michel Chezal
- Inserm, Imagerie Moléculaire et Stratégies Théranostiques, UMR 1240, Université Clermont Auvergne, F-63000 Clermont-Ferrand, France; (M.N.C.); (J.-M.C.); (E.D.); (D.C.); (T.W.); (S.L.); (F.D.); (S.T.); (E.M.-N.); (A.S.)
| | - Eric Debiton
- Inserm, Imagerie Moléculaire et Stratégies Théranostiques, UMR 1240, Université Clermont Auvergne, F-63000 Clermont-Ferrand, France; (M.N.C.); (J.-M.C.); (E.D.); (D.C.); (T.W.); (S.L.); (F.D.); (S.T.); (E.M.-N.); (A.S.)
| | - Damien Canitrot
- Inserm, Imagerie Moléculaire et Stratégies Théranostiques, UMR 1240, Université Clermont Auvergne, F-63000 Clermont-Ferrand, France; (M.N.C.); (J.-M.C.); (E.D.); (D.C.); (T.W.); (S.L.); (F.D.); (S.T.); (E.M.-N.); (A.S.)
| | - Tiffany Witkowski
- Inserm, Imagerie Moléculaire et Stratégies Théranostiques, UMR 1240, Université Clermont Auvergne, F-63000 Clermont-Ferrand, France; (M.N.C.); (J.-M.C.); (E.D.); (D.C.); (T.W.); (S.L.); (F.D.); (S.T.); (E.M.-N.); (A.S.)
| | - Sophie Levesque
- Inserm, Imagerie Moléculaire et Stratégies Théranostiques, UMR 1240, Université Clermont Auvergne, F-63000 Clermont-Ferrand, France; (M.N.C.); (J.-M.C.); (E.D.); (D.C.); (T.W.); (S.L.); (F.D.); (S.T.); (E.M.-N.); (A.S.)
- Department of Nuclear Medicine, Jean Perrin Comprehensive Cancer Centre, F-63000 Clermont-Ferrand, France
| | - Françoise Degoul
- Inserm, Imagerie Moléculaire et Stratégies Théranostiques, UMR 1240, Université Clermont Auvergne, F-63000 Clermont-Ferrand, France; (M.N.C.); (J.-M.C.); (E.D.); (D.C.); (T.W.); (S.L.); (F.D.); (S.T.); (E.M.-N.); (A.S.)
| | - Sébastien Tarrit
- Inserm, Imagerie Moléculaire et Stratégies Théranostiques, UMR 1240, Université Clermont Auvergne, F-63000 Clermont-Ferrand, France; (M.N.C.); (J.-M.C.); (E.D.); (D.C.); (T.W.); (S.L.); (F.D.); (S.T.); (E.M.-N.); (A.S.)
| | - Barbara Wenzel
- Helmholtz-Zentrum Dresden-Rossendorf, Research Site Leipzig, Institute of Radiopharmaceutical Cancer Research, 04318 Leipzig, Germany;
| | - Elisabeth Miot-Noirault
- Inserm, Imagerie Moléculaire et Stratégies Théranostiques, UMR 1240, Université Clermont Auvergne, F-63000 Clermont-Ferrand, France; (M.N.C.); (J.-M.C.); (E.D.); (D.C.); (T.W.); (S.L.); (F.D.); (S.T.); (E.M.-N.); (A.S.)
| | - Audrey Serre
- Inserm, Imagerie Moléculaire et Stratégies Théranostiques, UMR 1240, Université Clermont Auvergne, F-63000 Clermont-Ferrand, France; (M.N.C.); (J.-M.C.); (E.D.); (D.C.); (T.W.); (S.L.); (F.D.); (S.T.); (E.M.-N.); (A.S.)
| | - Aurélie Maisonial-Besset
- Inserm, Imagerie Moléculaire et Stratégies Théranostiques, UMR 1240, Université Clermont Auvergne, F-63000 Clermont-Ferrand, France; (M.N.C.); (J.-M.C.); (E.D.); (D.C.); (T.W.); (S.L.); (F.D.); (S.T.); (E.M.-N.); (A.S.)
- Correspondence:
| |
Collapse
|